Avicanna Reduces Net Loss And Improves Gross Profit, Focusing On International Markets
Avicanna Reduces Net Loss And Improves Gross Profit, Focusing On International Markets
Avicanna Inc. (OTCQX:AVCNF) announced its financial results Thursday for the third quarter, disclosing revenue of CA$6.27 million ($4.49 million), compared to CA$6.25 million in the same period last year. The Toronto-based cannabis company also reported improved consolidated gross margin to 57% from 46% for the same period in 2023.
Avicanna Inc. (OTCQX:AVCNF)週四公佈了第三季度的財務結果，營業收入爲627萬加元（449萬美元），相比去年同期的625萬加元略有增長。這家位於多倫多的大麻股公司還報告了整體毛利率的改善，從2023年同期的46%上升至57%。
"We are pleased to report the results of another quarter showing progressive improvements across our four business pillars," stated CEO Aras Azadian. "Our continuous optimization efforts contributed to improvements in our overall financial performance, consolidated gross margins, and balance sheet. We are now better positioned to turn our attention towards our international growth initiatives and take further steps towards advancing our long-term business model."
首席執行官Aras Azadian表示：「我們高興地報告另一個季度的結果，顯示出我們四個業務支柱的持續改善。我們的持續優化工作促進了整體財務表現、合併毛利率和資產負債表的改善。我們現在處於更好的位置，能夠將注意力轉向我們的國際增長計劃，並朝着推進我們長期業務模式的方向採取進一步措施。」
Read Also: Agrify's Q3 Revenue Drop, $18.6M Loss Amid New Leadership
閱讀更多：Agrify第三季度營業收入下降，損失1860萬，在新領導下
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
訂閱本新聞快訊，每天免費獲取Benzinga獨家分析和大麻股行業及市場的最新資訊。如果您對業務認真，不容錯過。在這裏訂閱我們的新聞簡報。
Q3 Financial Highlights
Q3財務亮點
- Gross profit was CA$3.7 million compared to CA$2.9 million in the comparable quarter last year.
- 毛利潤爲370萬加元，而去年同期爲290萬加元。
- Adjusted EBITDA was a loss of CA$293,931 compared to adjusted EBITDA loss of $473,650 in the corresponding period last year.
- Net loss amounted to CA$786,388 compared to net loss of CA$1.42 million in the third quarter of 2023.
- Fully repaid outstanding principle balance of approximately CA$1.3 million owed under non-convertible debenture.
- 調整後的 EBITDA 虧損爲293,931加元，而去年同期的調整後 EBITDA 虧損爲473,650美元。
- 淨虧損爲786,388加元，而2023年第三季度的淨虧損爲142萬加元。
- 全額償還了大約130萬加元的非可轉換債券未償還本金餘額。
Recent Milestones
最近的里程碑
In August, the biopharmaceutical company announced the successful export of its Aureus-branded cannabigerol (CBG) products to Denmark. This marked the 19th international market for Aureus-branded products and the 22nd market overall for Avicanna's product range. The export was facilitated through Avicanna's majority-owned subsidiary, Santa Marta Golden Hemp SAS.
在八月份，這家生物製藥公司宣佈成功將其Aureus品牌的大麻酚(CBG)產品出口到丹麥。這標誌着Aureus品牌產品進入第19個國際市場，並且是Avicanna產品區間的第22個市場。此次出口通過Avicanna的控股子公司聖馬爾塔金麻SAS實現。
The same month, Avicanna closed a non-brokered private placement offering of its 6,620,692 units at $0.30 per unit for aggregate gross proceeds of $1,986,207.
同月，Avicanna完成了其6,620,692個單位的非中介定向增發，單位價格爲0.30美元，總代價毛利潤爲1,986,207美元。
This year also, the company confirmed that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. US 20230025693A1, covering the company's deep penetrating topical cannabinoid composition and methods for treating musculoskeletal inflammation and pain.
今年，公司還確認，美國專利商標局(USPTO)已發佈美國專利號US 20230025693A1，涵蓋公司深層滲透的局部大麻素組成及其治療肌肉骨骼炎症和疼痛的方法。
Price Action
股價變動
Avicanna shares closed Thursday's market session flat at 17 cents a share.
Avicanna的股份週四在市場收盤時持平，價格爲每股17美分。
- CV Sciences Q3: Revenue Stable Amid New Launches, Financing
- CV Sciences第三季度：在新產品發佈和融資中，營業收入保持穩定
Photo: Courtesy of Avicanna
照片：感謝Avicanna提供
譯文內容由第三人軟體翻譯。
